Impact of hyperkalaemia definition on incidence assessment: implications for epidemiological research based on a large cohort study in newly diagnosed heart failure patients in primary care

被引:6
作者
Martin-Perez, Mar [1 ]
Ruigomez, Ana [1 ]
Michel, Alexander [2 ]
Rodriguez, Luis A. Garcia [1 ]
机构
[1] Spanish Ctr Pharmacoepidemiol Res CEIFE, Madrid, Spain
[2] Bayer Pharma AG, Epidemiol, D-13342 Berlin, Germany
来源
BMC FAMILY PRACTICE | 2016年 / 17卷
关键词
Hyperkalaemia; Heart failure; Incidence; Cohort study; Primary care; ANGIOTENSIN-ALDOSTERONE SYSTEM; EJECTION FRACTION; GENERAL-PRACTICE; PREDICTORS; RISK; SPIRONOLACTONE; DYSFUNCTION; GUIDELINES; INHIBITORS; FREQUENCY;
D O I
10.1186/s12875-016-0448-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Various definitions of hyperkalaemia have been used in clinical research, and data from routine clinical practice on its incidence are sparse. We aimed to establish the incidence of hyperkalaemia in patients with newly diagnosed heart failure in the UK general population using different definitions for the condition. Methods: We conducted a large retrospective cohort study using data from The Health Improvement Network primary care database. Patients with newly diagnosed heart failure (N = 19,194) were identified and followed until the first occurrence of hyperkalaemia. Different serum potassium (K+) thresholds were evaluated as possible definitions for hyperkalaemia, and incidence rates (IRs) calculated using a final operational definition both overall and among patient sub-groups. Results: IRs of hyperkalaemia ranged from 0.92-7.93 per 100 person-years according to the definition. Based on considerable differences in the serum K+ normal range used between practices, 2176 (11.3 %) individuals were identified with a record of hyperkalaemia using our operational definition of a proportional increase of = 10 % above the upper bound of the normal range: IR 2.90 per 100 person-years (95 % CI 2.78-3.02) over a mean follow-up of 3.91 years. Incidence rates were higher in older patients, and in those with diabetes or renal impairment. Conclusions: Hyperkalaemia is a common finding in heart failure patients in primary care, but its incidence can vary nearly ten-fold depending on its definition. Since assessment of hyperkalaemia risk is essential for therapeutic decision making in heart failure patients, this finding warrants consideration in future epidemiological studies.
引用
收藏
页数:8
相关论文
共 26 条
  • [1] Blak Betina T, 2011, Inform Prim Care, V19, P251
  • [2] Complications of inappropriate use of spiroholactone in heart failure: When an old medicine spirals out of new guidelines
    Bozkurt, B
    Agoston, I
    Knowlton, AA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (02) : 211 - 214
  • [3] Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: A retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials
    de Denus, Simon
    Tardif, Jean-Claude
    White, Michel
    Bourassa, Martial G.
    Racine, Normand
    Levesque, Sylvie
    Ducharme, Anique
    [J]. AMERICAN HEART JOURNAL, 2006, 152 (04) : 705 - 712
  • [4] Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone System - Balancing risk and benefit
    Desai, Akshay
    [J]. CIRCULATION, 2008, 118 (16) : 1609 - 1611
  • [5] Incidence and predictors of hyperkalemia in patients with heart failure
    Desai, Akshay S.
    Swedberg, Karl
    McMurray, John V.
    Granger, Christopher B.
    Yusuf, Salim
    Young, James B.
    Dunlap, Mark E.
    Solomon, Scott D.
    Hainer, James W.
    Olofsson, Bertil
    Michelson, Eric L.
    Pfeffer, Marc A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (20) : 1959 - 1966
  • [6] The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
    Einhorn, Lisa M.
    Zhan, Min
    Hsu, Van Doren
    Walker, Lori D.
    Moen, Maureen F.
    Seliger, Stephen L.
    Weir, Matthew R.
    Fink, Jeffrey C.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (12) : 1156 - 1162
  • [7] Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction
    Hernandez, Adrian F.
    Mi, Xiaojuan
    Hammill, Bradley G.
    Hammill, Stephen C.
    Heidenreich, Paul A.
    Masoudi, Frederick A.
    Qualls, Laura G.
    Peterson, Eric D.
    Fonarow, Gregg C.
    Curtis, Lesley H.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (20): : 2097 - 2107
  • [8] Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease
    Jain, Nishank
    Kotla, Suman
    Little, Bertis B.
    Weideman, Rick A.
    Brilakis, Emmanouil S.
    Reilly, Robert F.
    Banerjee, Subhash
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (10) : 1510 - 1513
  • [9] Rates of hyperkalemia after publication of the randomized aldactone evaluation study
    Juurlink, DN
    Mamdani, MM
    Lee, DS
    Kopp, A
    Austin, PC
    Laupacis, A
    Redelmeier, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (06) : 543 - 551
  • [10] Lachaine Jean, 2011, BMC Clin Pharmacol, V11, P4, DOI 10.1186/1472-6904-11-4